MannKind Corp. (MNKD)

[COO2002COO]

Jefferies analyst Shaunak Deepak lowered estimate and his price target on MannKind (NASDAQ: MNKD) to $9.00 (from $10.00) but is maintaining a Buy rating.

Deepak commented, "Despite early IMS scripts, physician feedback has made us more confident in the long-term sales potential of Afrezza. While we are maintaining our peak estimates, we are now assuming the Afrezza trajectory will take ten years, rather than six. As a result of this more gradual sales ramp, we are lowering lowering our PT from $10 to $9."

The firm cut FY 2015 EPS from $0.41 to ($0.42).